Jean-Yves Scoazec
让-伊夫·斯科泽克
MD, PhD
Head of Pathology Department; Professor of Pathology病理科主任；病理学教授
👥Biography 个人简介
Prof. Jean-Yves Scoazec is Europe's foremost NET pathologist at Gustave Roussy. He has been instrumental in developing and refining WHO classification and grading systems for neuroendocrine neoplasms, defining pathological criteria that guide clinical decision-making worldwide.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
WHO NET Classification and Grading
Contributed centrally to WHO 2010 and 2019 classification systems for gastrointestinal and pancreatic neuroendocrine neoplasms, establishing Ki-67 and mitotic count grading criteria now universally applied.
NET Pathology Standardization
Led European pathology quality assurance initiatives to standardize NET diagnosis, grading, and reporting across centers, reducing interobserver variability in NET pathological assessment.
Representative Works 代表性著作
Pathological classifications of gastroenteropancreatic neuroendocrine neoplasms
Best Practice & Research Clinical Gastroenterology (2012)
Definitive review of evolving WHO classification frameworks for GEP-NENs, widely used by pathologists and clinicians to understand grading criteria and their clinical implications.
The 2019 WHO classification of tumours of the digestive system: neuroendocrine neoplasms
Histopathology (2019)
Key publication describing the 2019 WHO update introducing NEC/NET distinction refinements and mixed neoplasm categories, reshaping pathological practice.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
James Yao
MD Anderson Cancer Center
Matthew Kulke
Boston Medical Center / Boston University
Emily Bergsland
University of California, San Francisco (UCSF)
Eric Liu
Rocky Mountain Cancer Centers
关注 让-伊夫·斯科泽克 的研究动态
Follow Jean-Yves Scoazec's research updates
留下邮箱，当我们发布与 Jean-Yves Scoazec（Gustave Roussy Cancer Campus）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment